Literature DB >> 23295239

BPH in 2012: novel agents in treatment of BPH.

Bilal Chughtai1, Alexis Te.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23295239     DOI： 10.1038/nrurol.2012.250

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

Review 1.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

2.  Therapy: two birds, one stone: tadalafil is an effective treatment for men with both BPH-LUTS and ED.

Authors:  Nick Warde
Journal:  Nat Rev Urol       Date:  2011-11-15       Impact factor: 14.432

3.  Intra-abdominal pressure, LUTS, and tadalafil. Re: Andersson K-E, et al. tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol urodyn 2011;30:292-301.

Authors:  Paul G Cohen
Journal:  Neurourol Urodyn       Date:  2012-04-06       Impact factor: 2.696

4.  Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

5.  Saw palmetto. Serenoa repens. Also known as Serenoa serrulata, Sabal serrulata and the dwarf palm.

Authors:  Joanne Barnes
Journal:  J Prim Health Care       Date:  2009-12

6.  A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.

Authors:  Michael Marberger; Emmanuel Chartier-Kastler; Blair Egerdie; Kyu-Sung Lee; Joachim Grosse; Denise Bugarin; Jihao Zhou; Anand Patel; Cornelia Haag-Molkenteller
Journal:  Eur Urol       Date:  2012-10-12       Impact factor: 20.096

7.  Safety and toxicity of saw palmetto in the CAMUS trial.

Authors:  Andrew L Avins; Jeannette Y Lee; Catherine M Meyers; Michael J Barry
Journal:  J Urol       Date:  2012-10-09       Impact factor: 7.450

8.  Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.

Authors:  Amado Bechara; Salomon Romano; Adolfo Casabé; Sergio Haime; Pablo Dedola; Cecilia Hernández; Horacio Rey
Journal:  J Sex Med       Date:  2008-07-14       Impact factor: 3.802

9.  Saw palmetto for benign prostatic hyperplasia.

Authors:  Stephen Bent; Christopher Kane; Katsuto Shinohara; John Neuhaus; Esther S Hudes; Harley Goldberg; Andrew L Avins
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

10.  Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial.

Authors:  Brian T Helfand; Jeanette Y Lee; Victoria Sharp; Harris Foster; Michael Naslund; O Dale Williams; Kevin T McVary
Journal:  J Urol       Date:  2012-10-22       Impact factor: 7.450
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.